EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Quantifying the Impact of Ocrelizumab on Paramagnetic Rim Lesions in Multiple Sclerosis

Kimberly H Markowitz iD, Neha V Safi, Iliana Pliska-Bloch, Ulrike W Kaunzner, Ha Luu, Mert Sisman, Yi Wang, Thanh D Nguyen, Sandra Hurtado Rúa, Susan A Gauthier iD

Annals of Clinical and Translational Neurology · 2026-07 · 13 (7) · 1482-1487

DOI: 10.1002/acn3.70357 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, online erschienen am 10.03.2026. Verfasst von Kimberly H Markowitz und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Weill Cornell Medicine, New York, New York, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Multiple Sclerosis, Immunologic Factors, Brain. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, Genentech, National Center for Advancing Translational Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Paramagnetic rim lesions (PRLs) are a subset of chronic active multiple sclerosis (MS) lesions marked by iron‐laden microglia and macrophages. Ocrelizumab, a monoclonal antibody targeting CD20+ B cells, suppresses acute MS activity, but its effect on PRLs remains unclear. In a longitudinal study of 29 ocrelizumab‐treated patients with at least one PRL on quantitative susceptibility mapping (QSM), 97 PRLs were identified. Before treatment, PRLs showed higher QSM values than non‐PRLs ( p = 0.001), indicating iron enrichment. After treatment, PRLs demonstrated a greater QSM reduction ( p < 0.001), with an accelerated decline in susceptibility. These findings suggest ocrelizumab may attenuate iron‐related inflammation in PRLs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedMultiple SclerosisImmunologic FactorsBrainHumansFemaleAdultMagnetic Resonance ImagingMaleLongitudinal StudiesMiddle Aged

Stichwörter der Autor:innen

multiple sclerosisocrelizumabquantitative susceptibility mapping

Substanzen

Antibodies, Monoclonal, HumanizedocrelizumabImmunologic Factors

Autor:innen und Institutionen

  • Department of Neurology, Weill Cornell Medicine, New York, New York, USA.
  • Department of Radiology, Weill Cornell Medicine, New York, New York, USA.
  • Mathematics and Statistics, Cleveland State University, Cleveland, Ohio, USA.
  • Feil Family Brain and Mind Institute, Weill Cornell Medicine, New York, New York, USA.

ORCID-Profile: Kimberly H Markowitz, Susan A Gauthier

Förderung

  • NCATS NIH HHS
  • Genentech
  • National Center for Advancing Translational Sciences

Zitieren

APA

Markowitz, K. H., Safi, N. V., Pliska-Bloch, I., Kaunzner, U. W., Luu, H., Sisman, M., Wang, Y., Nguyen, T. D., Hurtado Rúa, S., & Gauthier, S. A. (2026). Quantifying the Impact of Ocrelizumab on Paramagnetic Rim Lesions in Multiple Sclerosis. Annals of Clinical and Translational Neurology, 13(7), 1482-1487. https://doi.org/10.1002/acn3.70357

Vancouver

Markowitz KH, Safi NV, Pliska-Bloch I, Kaunzner UW, Luu H, Sisman M, et al. Quantifying the Impact of Ocrelizumab on Paramagnetic Rim Lesions in Multiple Sclerosis. Annals of Clinical and Translational Neurology. 2026;13(7):1482-1487. doi:10.1002/acn3.70357

BibTeX
@article{Markowitz2026,
  author = {Markowitz, Kimberly H and Safi, Neha V and Pliska-Bloch, Iliana and Kaunzner, Ulrike W and Luu, Ha and Sisman, Mert and Wang, Yi and Nguyen, Thanh D and Hurtado Rúa, Sandra and Gauthier, Susan A},
  title = {Quantifying the Impact of Ocrelizumab on Paramagnetic Rim Lesions in Multiple Sclerosis},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2026},
  volume = {13},
  number = {7},
  pages = {1482--1487},
  doi = {10.1002/acn3.70357}
}
Kostenlos starten →